Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response

.

Source: OncoImmunology - April 18, 2019 Category: Cancer & Oncology Authors: Fulvia Vascotto Jutta Petschenka Kerstin C. Walzer Mathias Vormehr Magdalena Brkic Stefan Strobl Roman R ösemann Mustafa Diken Sebastian Kreiter Özlem Türeci Ugur Sahin Source Type: research